Clinical Research Directory

Inclusion Criteria: * Ability to understand and willingness to sign an informed consent form * At least 18 years of age * Histologically confirmed advanced solid tumors * Patients must have grade 2 or 3 irAEs from at least one ICI-containing regimen. Both newly emerging and persistent irAEs are allowed. Systemic steroid therapy or any other form of immunosuppressive therapy for irAEs is allowed. The specific irAEs are * Grade 2-3 diarrhea/colitis: Patients with \>= 4 stools per day or moderate-severe increase in ostomy output compared to baseline but not life-threatening diarrhea * Grade 2-3 pneumonitis: Mild to moderate (grade 2) or severe (grade 3) symptoms (including hypoxia, shortness of breath, requiring oxygen) but not life-threatening respiratory compromise requiring urgent intervention (e.g., tracheostomy or intubation) * Grade 2-3 renal irAE: Creatine increased between 1.6-6.0 x upper limit of normal (ULN) or =\< 3.0 x baseline if baseline was abnormal, estimated glomerular filtration rate (eGFR) or creatinine clearance \>= 15 ml/min/1.73m\^2 but not life-threatening consequences or requiring dialysis * Grade 2-3 Hepatic irAE: AST/ALT/ALP levels 3-20 x ULN, and T bilirubin increased \<5 x ULN * Grade 2-3 skin rash: moderate (10-30% body surface area, BSA) to severe (\> 30% BSA) but not life-threatening skin lesions or Stevens-Johnson syndrome * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 * Life expectancy of \>= 3 months at the time of enrollment * Pretreatment absolute neutrophil count (ANC) \>= 1,000/uL obtained within 14 days prior to 1st dose of treatment * Pretreatment hemoglobin \>= 8 gm/dL obtained within 14 days prior to 1st dose of treatment * Pretreatment platelet count of \>= 75,000/uL obtained within 14 days prior to 1st dose of treatment * Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for \>= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration * Male and female subjects who agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices \[IUDs\], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 90 days after the last dose of study drug Exclusion Criteria: * Prior CD24Fc therapy * Any known active hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, including patients who have an active infection requiring systemic therapy. History of COVID-19 or known asymptomatic carrier of SARS-CoV-2 virus is allowed * Pregnant or lactating women * Any medical condition including additional laboratory abnormalities, or psychiatric illness that would, in the opinion of the investigator, prevent the subject from participating and adhering to study related procedures * Any known severe bacterial, fungal, or viral infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 2 weeks prior to enrollment * Patients with concomitant proarrhythmic medications * Patients with heart failure in New York (NY) Heart Association stage IV * Any grade 4 irAE symptoms and Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 grade 4 toxicity * AST, ALT, gamma glutamyl transpeptidase (GGT), or ALP \> 20.0 x ULN regardless of baseline * Blood bilirubin \>5.0 x ULN regardless of baseline * Creatinine \> 6.0 x ULN or creatinine clearance \<15 ml/min/1.73m2 * Urine: Anuria \< 140 ml in 24 hours * Electrolytes hyponatremia, sodium \< 120 mmol/L * Hypokalemia, potassium \< 2.5 mmol/L * Creatine kinase (CPK) \> 10.0 ULN * Electrocardiogram (ECG): Prolonged QT interval \>= 480 mS, corrected by Fridericia's formula. Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrythmia